ChemDiv Helps Advance Viriom’s Influenza Treatment to Successful Phase I Clinical Trials Completion
ChemDiv Inc., dedicated to partnering in discovery and development of breakthrough therapies based on its unique chem-bio platforms, announces successful completion of Phase I clinical trials for AV5124, an innovative influenza virus replication inhibitor being developed by Viriom Inc. (Viriom)….
Viriom’s Single Pill Influenza Treatment Completes Critical Phase I Clinical Trials
Viriom Inc., dedicated to advancing a pipeline of highly effective and broadly affordable treatments targeting infectious and malignant diseases globally, announces the successful completion and positive results of Phase I clinical trial for AV5124, a novel inhibitor of influenza virus…
